---
layout: post
published: FALSE
title: What's new for 'childhood cancer' in PubMed
date: '2011-10-15T11:42:00.002-03:00'
author: Francisco H C Felix
tags:
- Cancer
lang: en-us
ref:
modified_time: '2011-10-15T11:42:38.494-03:00'
blogger_id: tag:blogger.com,1999:blog-2993346515708552092.post-3457182050230951676
blogger_orig_url: https://pharmak.blogspot.com/2011/10/whats-new-for-childhood-cancer-in.html
---

This message contains My NCBI what's new results from the National Center for Biotechnology <br /><b>Sender's message: </b> <br />Sent on Saturday, 2011 Oct 15<br />Search <b>cancer</b> <br /><div>Limits:<b>Randomized Controlled Trial, All Child: 0-18 years</b></div><div><br /><br /><div><table bgcolor="#CCCCCC"><tbody><tr><td align="center">PubMed Results</td></tr></tbody></table></div><br /><div><table cellpadding="0" cellspacing="5"><tbody><tr><td nowrap="nowrap" valign="top" width="10">1.</td><td valign="top"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21788220" ref="ordinalpos=1">A randomized controlled trial of propranolol for infantile hemangiomas.</a></td></tr><tr><td align="left" valign="top" width="10"><br /></td><td align="left" valign="top">Hogeling M,  Adams S,  Wargon O.</td></tr><tr><td align="left" valign="top" width="10"><br /></td><td align="left" valign="top"><span class="jrnl" title="Pediatrics">Pediatrics</span>. 2011 Aug;128(2):e259-66. Epub 2011 Jul 25.</td></tr><tr><td align="left" valign="top" width="10"><br /></td><td align="left" valign="top">PMID: 21788220 [PubMed - indexed for MEDLINE]<br /><br /><b>RCT demonstrated propranolol effect in hemangiomas of infancy. Now cleared as first choice?</b><br /></td></tr></tbody></table><table cellpadding="0" cellspacing="5"><tbody><tr><td nowrap="nowrap" valign="top" width="10">2.</td><td valign="top"><a href="https://www.ncbi.nlm.nih.gov/pubmed/21681921" ref="ordinalpos=4">Soluble interleukin-2 receptor Î± activation in a Children's Oncology Group randomized trial of interleukin-2 therapy for pediatric acute myeloid leukemia.</a></td></tr><tr><td align="left" valign="top" width="10"><br /></td><td align="left" valign="top">Lange BJ,  Yang RK,  Gan J,  Hank JA,  Sievers EL,  Alonzo TA,  Gerbing RB,  Sondel PM.</td></tr><tr><td align="left" valign="top" width="10"><br /></td><td align="left" valign="top"><span class="jrnl" title="Pediatric blood &amp;  cancer">Pediatr Blood Cancer</span>. 2011 Sep;57(3):398-405. doi: 10.1002/pbc.22966. Epub 2011 Jun 16.</td></tr><tr><td align="left" valign="top" width="10"><br /></td><td align="left" valign="top">PMID: 21681921 [PubMed - indexed for MEDLINE]<br /><br /><b>Unfortunately, this large immunotherapy trial in pediatric AML did not show effect of IL-2 in disease free survival or overall survival.</b> </td></tr></tbody></table></div></div>
